Blog Archive
-
▼
2008
(233)
-
▼
April
(49)
- Echo : Prelude SkinPrep System, the Next-Generatio...
- Rigel's R788 : Preclinical Activity in Type 1 Diab...
- Pelikan and Lilly : Diabetes Education Alliance
- Smiths Medical to Promote and Distribute Abbott’s ...
- Medtronic : FDA Clearance of New OneTouch Ultralin...
- Metabasis Therapeutics : Extension of Its Collabor...
- Hadasit : Successful Phase I Study Results of a Ne...
- Innocoll : Phase 2 Clinical Trial to Investigate C...
- Pacira Pharmaceuticals and Amylin Pharmaceuticals ...
- Tolerx : Advancing Novel Type 1 Diabetes Agent int...
- Biovitrum : unique neuropathic pain compound is ve...
- SciGen and Generex : Distribution Agreement for Or...
- MetaCure : NewYork-Presbyterian/Weill Cornell Is F...
- GlaxoSmithKline to acquire Sirtris Pharmaceuticals...
- Medicure : Presentation of Phase II Matched Result...
- Daiichi Sankyo : Welchol Added to the ACE/AACE "Ro...
- AtheroGenics : Encouraging Interim Results From Ph...
- Pacific Biometrics : Research Contracts as Part of...
- AGI Therapeutics : key findings of clinical PK stu...
- Living Cell Technologies : Proprietary Nanobiocaps...
- Karo Bio : Positive Results in First Clinical Stud...
- Elixir Pharmaceuticals : National Diabetes Advisor...
- BioChemics & Beth Israel Deaconess Medical Center ...
- DiaKine : Lisofylline Reduces Obesity-Related Infl...
- PerkinElmer : New Innovations to Strengthen Drug D...
- Exelgen : Two New Major Drug Discovery Collaborat...
- Entelos : U.S. Patent for its Diabetes Model
- Kamada : AAT proved efficient in treating Type-1 ...
- Home Test Kits from BioIQ Help Consumers Detect Di...
- DiaKine Therapeutics & Kinexum Metabolics : Combin...
- 12-Month Data from Endeavor IV Show Strong Clinica...
- ArthroCareSports Medicine : to Tackle Diabetic Fo...
- WellDoc Communications : Diabetes Management Progr...
- Elixir Pharmaceuticals : enrollment in its final p...
- Pfizer Statement on Exubera Labeling Update in the US
- Diabetech Launches GlucoMON-RT Real-Time Monitorin...
- Luminous Medical : Automated Blood Glucose Monitor...
- Alimera Sciences and pSivida : DSMB again support...
- Metabolex : Phase 1 clinical trial of MBX-2982, Po...
- Takeda : ACTOS® (pioglitazone HCl) Prevented Progr...
- Cardium and Tissue Repair Company's Excellarate : ...
- Smiths Medical MD : voluntary recall of specific s...
- Owen Mumford Ltd : to discontinue Unilet GP and U...
- CV Therapeutics : New Data Shows Ranexa Increases ...
- Senesco : Preclinical Pancreatic Islet Data to be ...
- Aegera : Phase 1 Clinical Trial of AEG33773 - a Sm...
- Oculus Innovative Sciences : Chinese SFDA Regulato...
- BioMimetic Therapeutics Addresses FDA Communicatio...
- Novo Nordisk : FDA Approves NovoLog for Use in In...
-
▼
April
(49)
Monday, April 14, 2008
Home Test Kits from BioIQ Help Consumers Detect Diabetes
April 09, 2008 – The number of Americans at risk for diabetes, heart disease, prostate cancer, colorectal cancer and other common illnesses has increased significantly in recent years, potentially shortening the lifespan of millions and putting an unprecedented strain on the health care system. Fortunately, with early detection and appropriate treatment, the complications and costs related to these diseases can often be minimized. Now thanks to a line of test kits from BioIQ, people can order test kits to blood sugarcholesterol, blood sugar and other important biometric information. BioIQ also offers corporate health screening programs to bring the benefits of home testing to employers, employees and their dependents, enabling people throughout the U.S. to screen themselves for many of today’s most common and preventable illnesses in the privacy of their own homes... BioIQ's Press Release -